Zimmer Biomet (NYSE:ZBH) Given Neutral Rating at BTIG Research

BTIG Research reiterated their neutral rating on shares of Zimmer Biomet (NYSE:ZBH) in a report released on Monday morning, MarketBeat reports.

A number of other analysts have also issued reports on the company. The Goldman Sachs Group lowered Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Friday, January 9th. Wells Fargo & Company increased their price target on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 11th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and raised their price objective for the company from $94.00 to $120.00 in a report on Monday, January 5th. Citigroup restated a “buy” rating on shares of Zimmer Biomet in a research report on Wednesday, February 11th. Finally, Robert W. Baird restated a “neutral” rating and set a $100.00 price target (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Zimmer Biomet presently has an average rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $87.78 on Monday. Zimmer Biomet has a 52-week low of $84.59 and a 52-week high of $114.44. The company has a 50-day simple moving average of $92.04 and a 200 day simple moving average of $94.47. The company has a market capitalization of $17.17 billion, a PE ratio of 24.80, a price-to-earnings-growth ratio of 1.79 and a beta of 0.58. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, research analysts predict that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 2,650 shares of the business’s stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at $967,803.84. The trade was a 20.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Zimmer Biomet

A number of large investors have recently made changes to their positions in the business. Advisortrust Partners LLC purchased a new stake in Zimmer Biomet in the fourth quarter worth $442,000. Corient Private Wealth LLC increased its position in Zimmer Biomet by 11.5% during the 4th quarter. Corient Private Wealth LLC now owns 46,989 shares of the medical equipment provider’s stock valued at $4,230,000 after purchasing an additional 4,863 shares during the period. Auto Owners Insurance Co increased its position in Zimmer Biomet by 8,892.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,009,712 shares of the medical equipment provider’s stock valued at $180,713,000 after purchasing an additional 1,987,362 shares during the period. Pacer Advisors Inc. raised its holdings in Zimmer Biomet by 4,020.2% in the 4th quarter. Pacer Advisors Inc. now owns 697,753 shares of the medical equipment provider’s stock worth $62,742,000 after purchasing an additional 680,818 shares in the last quarter. Finally, Monetary Solutions Ltd bought a new position in Zimmer Biomet in the 4th quarter worth $30,000. 88.89% of the stock is currently owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.